Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision

Brožek, Jan; Bousquet, Jean; Agache, Ioana; Agarwal, Arnav; Bachert, Claus; Bosnic‐Anticevich, Sinthia; Brignardello‐Petersen, Romina; Canonica, Giorgio Walter; Casale, Thomas B.; Chavannes, Niels H.; Sousa, Jaime Correia de; Cruz, Álvaro Augusto; Cuello-Garcia, Carlos A.; Demoly, Pascal; Dykewicz, Mark S.; Etxeandia-Ikobaltzeta, Itziar; Flórez, Iván D.; Fokkens, Wytske J.; Fonseca, João; Hellings, Peter W.; Klimek, Ludger; Kowalski, Sérgio Cândido; Kuna, Piotr; Laisaar, Kaja Triin; Larenas‐Linnemann, Désirée; Carlsen, Karin C. Lødrup; Manning, Peter J.; Meltzer, Eli O.; Mullol, Joaquim; Muraro, Antonella; O’Hehir, Robyn E; Ohta, Ken; Panzner, Petr; Papadopoulos, Nikolaos G.; Park, Hae‐Sim; Passalacqua, G.; Pawankar, Ruby; Price, David; Riva, John J.; Roldán, Yetiani; Ryan, Dermot; Sadeghirad, Behnam; Samoliński, Bolesław; Schmid‐Grendelmeier, Peter; Sheikh, Aziz; Togias, Alkis; Valero, Antonio; Valiulis, Arūnas; Valovirta, Erkka; Ventresca, Matthew; Wallace, Dana; Waserman, Susan; Wickman, Magnus; Wiercioch, Wojtek; Yepes-Núñez, Juan José; Zhang, Luo; Zhang, Yuan; Zidarn, Mihaela; Zuberbier, Torsten; Schünemann, Holger J.

doi:10.1016/j.jaci.2017.03.050

Cited by 1,434 publications

(1,406 citation statements)

References 39 publications

Supporting

Mentioning

1,129

Contrasting

Unclassified

145

Order By: Relevance

“…In addition, at more than 6 h after the challenge, nasal obstruction following swelling of the nasal mucosa results from the late-phase reaction caused by Th2 cytokines, various chemical mediators and chemokines [1]. In the present study, sneezing and nasal rubbing right after the last nasal challenge were attenuated by the administration of SH-2251.…”

Section: Discussionsupporting

confidence: 47%

See 1 more Smart Citation

Suppressive Effect of a Thioamide-Related Compound SH-2251 on a Murine Allergic Rhinitis Model

Kitani¹,

Maruyama²,

Aoishi³

et al. 2017

J Allergy Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 47%

“…Allergic rhinitis (AR) affects 10% to 40% of the world's population [1]. AR generally indicates nasal mucosal inflammation characterized by IgE-mediated allergic immune responses [2].…”

Section: Introductionmentioning

confidence: 99%

Suppressive Effect of a Thioamide-Related Compound SH-2251 on a Murine Allergic Rhinitis Model

Kitani¹,

Maruyama²,

Aoishi³

et al. 2017

J Allergy Ther

View full text Add to dashboard Cite

show abstract

“…Based on the pathophysiology of the disease, corticosteroids are one of the main treatment options that prevent or suppress inflammation and immune responses to the inciting specific allergen in patients with PAR. The updated Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines (2016) recommend the use of intranasal corticosteroids alone over the combination with oral H 1 antihistamines in PAR treatment [9]. In an international cross-sectional survey study conducted among otolaryngologists from Asia, Africa, Europe, and the Americas, 52 responses were obtained for the question “Which types of symptomatic drugs do you prescribe in allergic patients?” to which multiple answers were possible.…”

Section: Introductionmentioning

confidence: 99%

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Karaulov

Vylegzhanina

Овчинников

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Intranasal sprays are recommended as targeted therapy for allergic rhinitis (AR). Triamcinolone acetonide is a nasal corticosteroid preparation indicated for the treatment of seasonal and perennial AR (PAR) in different countries worldwide. Objectives: In order to determine the efficacy of triamcinolone acetonide in the treatment of PAR, the non-inferiority of triamcinolone acetonide to fluticasone propionate was assessed in Russian adults. Methods: In this randomized, double-blind, parallel-group, multicenter, prospective, non-inferiority, phase III clinical trial, a total of 260 patients with persistent PAR were randomized to receive either triamcinolone acetonide or fluticasone propionate nasal sprays for 4 weeks. The efficacy in symptom control was evaluated using the reflective total nasal symptom score (rTNSS) from baseline (day 0) to day 28. Safety was assessed through the reporting of adverse events. Results: The rTNSS mean values decreased from baseline to the end of study treatment (day 28) in both groups: –8.2 ± 3.0 in the triamcinolone acetonide arm versus –8.0 ± 2.8 in the fluticasone propionate arm. The mean difference between the groups (triamcinolone acetonide – fluticasone propionate) for rTNSS change from baseline was –0.2 (95% confidence interval –0.89 to 0.54), with an upper confidence limit of 0.54, which is lower than the non-inferiority margin of 0.8. Triamcinolone acetonide was well tolerated, with no difference in adverse event occurrence compared with fluticasone propionate. Conclusions: Triamcinolone acetonide proved to be non-inferior to fluticasone propionate in adult patients with PAR; both treatments decreased rTNSS values and showed a good safety profile.

show abstract

“…Moderate-to-severe PER was defined according to ARIA guidelines as sleep disturbance and/or impaired daily activities occurring on at least 4 days per week for at least 4 weeks [22]. …”

Section: Methodsmentioning

confidence: 99%

Sensitization to Cat: When Is Nasal Challenge Needed?

Al‐Ahmad

Jusufović

Arifhodžić

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Introduction: Although the skin prick test (SPT) is a reliable diagnostic tool in perennial allergic rhinitis (PER) for patients allergic to cats, the minimum necessary SPT wheal size required to distinguish cat sensitization from true allergy remains controversial. The cat nasal challenge test (cNCT) could be considered the gold standard for detecting true cat allergy. Aims: To assess the difference in the frequency of cNCT positivity between cat owners and non-owners and to determine an appropriate cut-off level for SPT wheal size in detecting positive cNCT in PER patients who are candidates for allergen immunotherapy (AIT) with cat allergen extracts. Subjects and Methods: cNCT in the form of a nasal spray was administered to 60 adult patients with PER, i.e., cat owners (n = 19) and cat non-owners (n = 41) with positive SPT to cat fur allergen (Diater, Spain). Subjective (total nasal symptom score [TNSS]) and objective measurements (peak nasal inspiratory flow [PNIF]) for assessment of nasal patency and nasal eosinophil count [NEo]) were used to assess the nasal response. Peak expiratory flow (PEF) was used as a safety parameter during cNCT. Results: No differences were obtained in SPT wheal size and cNCT positivity between cat owners and non-owners. Positive cNCT detecting true cat allergy could be predicted by a cat SPT wheal size > 6.5 mm with 71.11% sensitivity and 100% specificity. Conclusions: In adult patients with PER, the frequency of cat allergy was similar among cat owners and non-owners. A cat SPT wheal size ≥6.5 mm could be helpful in detecting true cat allergy by avoiding the demanding, time-consuming, and often unavailable cNCT when cat AIT is needed.

show abstract

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision

Abstract: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.

Cited by 1,434 publications

References 39 publications

Suppressive Effect of a Thioamide-Related Compound SH-2251 on a Murine Allergic Rhinitis Model

Suppressive Effect of a Thioamide-Related Compound SH-2251 on a Murine Allergic Rhinitis Model

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Sensitization to Cat: When Is Nasal Challenge Needed?

Contact Info

Product

Resources

About